Ionetix Q2 FY26: revenue $1.2M; diluted EPS −$0.15
- Form
- 10-Q
- Filed
- Period
- Importance
- Notable
- Accession
- 0001213900-26-088309
Key figures from this report
These are the numbers Ionetix reported for Q2 FY26, the quarter ended Jun 30, 2026, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.
- Revenue$1.2MNo year-earlier figure tagged10-Q income statement, on EDGAR
- Net income−$15.3MNo year-earlier figure tagged10-Q income statement, on EDGAR
- Diluted EPS−$0.15No year-earlier figure tagged10-Q income statement, on EDGAR
- Cash and cash equivalents$10.9MNo year-earlier figure tagged10-Q balance sheet, on EDGAR
- Cash from operations−$9.5MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters
Similar companies
Same SIC code (2835) and public float not reported.
- Burzynski Research Institute BZYR
- Anbio Biotechnology NNNN
- Nymox Pharmaceutical NYMXF
- Asep Medical Holdings SEPSF
- Trinity Biotech TRIB